Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Liabilities and Shareholders Equity: 2022-2024

Historic Liabilities and Shareholders Equity for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to $582.8 million.

  • Day One Biopharmaceuticals' Liabilities and Shareholders Equity fell 14.49% to $513.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year increase of 26.18%. This contributed to the annual value of $582.8 million for FY2024, which is 54.98% up from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Liabilities and Shareholders Equity of $582.8 million as of FY2024, which was up 54.98% from $376.0 million recorded in FY2023.
  • In the past 5 years, Day One Biopharmaceuticals' Liabilities and Shareholders Equity registered a high of $582.8 million during FY2024, and its lowest value of $349.1 million during FY2022.
  • In the last 3 years, Day One Biopharmaceuticals' Liabilities and Shareholders Equity had a median value of $376.0 million in 2023 and averaged $436.0 million.
  • Data for Day One Biopharmaceuticals' Liabilities and Shareholders Equity shows a peak YoY surged of 54.98% (in 2024) over the last 5 years.
  • Over the past 3 years, Day One Biopharmaceuticals' Liabilities and Shareholders Equity (Yearly) stood at $349.1 million in 2022, then rose by 7.73% to $376.0 million in 2023, then surged by 54.98% to $582.8 million in 2024.